创新驱动未来 Innovation Drives Future
ADC 的未来 Building the Future of ADC with Innovation
佰睿壹生物专注于抗体偶联药物（ADC）的底层技术创新和下一代 ADC 药物的研发，致力于为全球患者带来突破性的治疗方案。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of next-generation ADC therapeutics, committed to bringing breakthrough treatments to patients worldwide.
Empowering the Future of ADC Innovation 用技术创新构建ADC 的未来
佰睿壹生物专注于抗体偶联药（ADC）的底层技术创新和双载荷 ADC 药物开发。作为抗体链间二硫键选择性还原技术的开拓者，我们开发了系统性化学定点偶联技术平台 MCLICK，该平台能够实现非常多样的 ADC DAR 值和双载荷 ADC 的比例，支持单载荷 AXC 和双载荷 ADC 的精细化设计。同时，抗体链间二硫键选择性还原 / 偶联的技术路径具有卓越的兼容性、广泛的适用性和明确且非常友好的 CMC 成本优势，是赋能 First-in-Class 和 Best-in-Class ADC 差异化创新的强大工具。 Bio-reinnovation focuses on fundamental technological innovation in Antibody-Drug Conjugates (ADC) and the development of dual-payload ADC drugs. As a pioneer of interchain disulfide bond selective reduction technology, we have developed the systematic site-specific chemical conjugation platform MCLICK, which enables highly diverse ADC DAR values and dual-payload ADC ratios, supporting the precise design of both single-payload AXC and dual-payload ADCs. Meanwhile, the interchain disulfide bond selective reduction / conjugation approach offers excellent compatibility, broad applicability, and clear, highly favorable CMC cost advantages, making it a powerful tool to empower First-in-Class and Best-in-Class ADC differentiated innovation.
MCLICK® Platform · Systematic Site-specific Conjugation
MCLICK® 平台 · 系统性化学定点偶联
MCLICK™
HILT
UDAC
DPAC
技术优势 Technical Advantages
ADC领域痛点 ADC Challenges
- 单载荷ADC耐药性问题 Resistance in Single-Payload ADCs
- 收率较低、酶催化偶联技术导致工艺成本较大 Low Yield and High Process Costs with Enzyme-Catalyzed Conjugation
- 双载荷ADC可选DAR值较为单一 Limited DAR Options in Dual-Payload ADCs
- 传统巯基偶联技术的不足 Limitations of Traditional Thiol Conjugation
佰睿壹优势 Our Advantages
- 双载荷ADC可解决耐药性问题 Dual-Payload ADCs Address Resistance
- 巯基化学定点偶联技术，大幅降低CMC成本 Site-Specific Thiol Conjugation Reduces CMC Costs
- 最丰富的的双载荷ADC可选DAR值比例 Most Diverse DAR Ratio Options for Dual-Payload ADCs
技术对照矩阵 Technology Comparison Matrix
告别传统的妥协。佰睿壹生物 MCLICK™ 平台在所有关键维度上均展现出了压倒性的优势。 Say goodbye to traditional compromises. Bio-Reinno's MCLICK™ platform demonstrates overwhelming advantages across all key dimensions.
| 关键特性Key Feature |
MCLICK™
佰睿壹生物独家
Bio-Reinno Exclusive
|
传统巯基 (示例)Traditional Thiol | 酶介导 (示例)Enzyme-mediated |
|---|---|---|---|
| DAR 灵活性 (单/双载荷)DAR Flexibility (Mono/Dual) | 极高Excellent | 受限Limited | 中等Moderate |
| 无酶工艺纯化Enzyme-free Process | 支持Yes | 支持Yes | 不支持No |
| 抗体兼容性Antibody Compatibility | 完美兼容Excellent | 良好Good | 受限Limited |
| 多载荷适用性Multi-payload Applicability | 完美支持Yes | 不支持No | 受限Limited |
| CMC 成本效益与收率CMC Cost Efficiency & Yield | 极高High | 中等Moderate | 较低Lower |
产品管线 Product Pipeline
我们的双有效载荷ADC管线经过精心设计，通过创新的MOA组合，针对高发病率、异质性强、耐药性高的肿瘤，显著拓展适应症范围。通过克服TOP1耐药、优于单载荷ADC，并与免疫治疗协同，致力于解决未满足的医疗需求。 Our dual payload ADC pipeline leverages innovative MOA combinations to address tumors with high incidence, strong heterogeneity, and significant drug resistance, aiming to provide superior treatment options and address unmet medical needs.